Testing CD34+ stem cell transplants for blood cancers
Tests a processed stem cell transplant in adults with acute myeloid leukemia.
Key facts
- Who runs it
- Guenther Koehne
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- CD34+ Transplants for Myeloid Malignancies
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Starts
- Jan 2027
- Expected to end
- Jan 2034
- Type of study
- Interventional
- Treatments tested
- Busulfan
- Melphalan
- Fludarabine
- CD34+ Allogeneic Peripheral Blood Stem Cell Transplant
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain blood cancers, such as acute myeloid leukemia, who need a stem cell transplant. The stem cells are processed with the CliniMACS system before transplant.
- Age
- 18 to 70 years. People aged 65 to 70 are studied as a separate group.
- Sex
- All sexes can join.
- Disease stage
- Blood cancers or blood disorders treated by transplant, for example: AML in first remission without good-risk gene features, secondary AML in first remission, AML in first relapse or second remission, CML not responding to TKI therapy or in advanced phases, CMML-1 and CMML-2, intermediate to high-risk myelofibrosis.
- Biomarker or test result
- Needs a donor who is a good tissue-type pair: related or unrelated 8/8, or unrelated 7/8 with one mismatch at HLA-A, B or DR-B1.
Main reasons for not taking part
- Pregnant or breast-feeding
- Uncontrolled infection, or known HIV, hepatitis B or hepatitis C infection (some hepatitis cases are allowed)
- Leukemia in the central nervous system
- Symptomatic heart disease, or heart pumping function (LVEF) below 50%
- Another active cancer, unless disease-free for at least 2 years
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Malignant conditions or other life-threatening disorders correctable by transplant for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as:; AML in 1st remission-- for patients whose AML does not have "good risk" cytogenetic features (i.e., t(8;21), (q22; q22.1); RUNX1-RUNX1T1, inv16); Secondary AML in 1st remission; AML in 1st relapse or 2nd remission; CML not responding adequately to TKI therapy, CML in accelerated phase or blast crisis, or CML in CR after accelerated phase or blast crisis; Chronic myelomonocyte leukemia: CMML-1 and CMML-2; Intermediate to high-risk primary or secondary myelofibrosis
- Patients aged ≥18 and ≤70 years old. Patients 65-70 years old will be examined as a separate cohort, since myeloablative regimens have been shown to be associated with increased morbidity, mortality, and toxicity in older patients, specifically, patients above 65 years of age (49)
- Patients may be of either gender or any ethnic background
- Patients must have an appropriately matched donor (MRD 8/8, MUD 8/8, or MMUD 7/8 [mismatch at HLA-A, B or DR-B1 locus])
- Patients may be of any sex, gender, or ethnic background
- Patients must have a Karnofsky (adult) Performance Status of at least 70%
- Patients must have adequate organ function measured by:; Cardiac: asymptomatic; left ventricular ejection fraction (LVEF) at rest must be ≥50%; Hepatic: < 3 × ULN AST and: < 1.5 × ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant (e.g., AML Chloroma obstructing the biliary tree). Patients with higher bilirubin levels due to causes other than active liver disease are also eligible with Pl approval e.g., patients with PNH, Gilbert's disease or other hemolytic disorders; Renal: serum creatinine: within normal range 0.7-1.3 mg/dL or if serum creatinine is outside the normal range, then CrCl > 45 mL/min (measured or calculated/estimated via Cockcroft-Gault formula); Pulmonary: asymptomatic [but sustained DLCO ≥ 50% of predicted (corrected for hemoglobin)]; Each patient must be willing to participate as a research subject and must sign an informed consent form
Who cannot take part
- Uncontrolled bacterial, viral, or fungal infections; or known human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection; Patients cured of Hepatitis C for ≥3 years prior to enrollment are permitted; Patients with detectable hepatitis B surface antigen (HBsAg) will be excluded. Patients with viral hepatitis B core antibody (HBcAb) positivity, but absence of HBsAg, will be eligible if HBV DNA is undetectable and if they are willing to be on hepatitis B antiviral prophylaxis and undergo monitoring for HBV reactivation (every 12 weeks while on immune suppression) per institutional protocols. Patients will be referred promptly to hepatology specialist with the first detectable viral load
- History of cardiovascular disease including but not limited to myocardial infarction, unstable angina, stroke, or transient ischemic attack within the 6 months prior to the initiation of study or congestive heart failure (New York Heart Association [NYHA] class III-IV)
- Patients who subsequently receive a non-T-cell-depleted transplant
- Have a history of other active malignancy(ies) unless the patient has been disease-free for at least 2 years and is deemed by the treating Investigator to be at low risk for recurrence of that malignancy; or the only prior cancer is curatively treated cervical cancer in situ, or basal cell or squamous cell carcinoma of the skin
- Symptomatic cardiac disease (angina, congestive heart failure) and/or LVEF <50%
- Stem cell count <3.0 × 10\^6/kg after CD34+ selection
- Individuals who are pregnant or breast-feeding
- Presence of leukemia in the CNS
- Known sensitivity to components of CliniMACS® Prodigy CD34 System
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Baptist Health Herbert Wertheim Cancer InstituteMiami, United StatesContact: Guenther Koehne, MD, Ph.D.Not yet recruiting
About the trial
What the trial wants to find out
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.
The group in the trial
- Busulfan/Melphalan/Fludarabine ConditioningTreatment being tested
Conditioning: * Busulfan, IV 0.8 mg/kg q6hours × 12 doses over 3 days * Melphalan,70 mg/m²/day × 2 days (or 50 mg/m²/day × 2 days for patients ≥65 years with a comorbidity index score of ≥3) via IV infusion over 30 minutes daily * Fludarabine, 25 mg/m²/day × 5 days via IV infusion over 30 minutes daily CD34+ Allogenic Peripheral Blood Stem Cell Transplant
Treatment: Busulfan, Melphalan, Fludarabine, and CD34+ Allogeneic Peripheral Blood Stem Cell Transplant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myeloid Malignancies
- Plain-language title
- Testing CD34+ stem cell transplants for blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05565105, who can take part
- Record updated
- 13 October 2026